Fig. 1From: Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD studyDistribution of certolizumab serum levels (total inflammatory joint disease population) at 3 months, mg/L. Median (IQR) 32.9 (17.3–43.9)Back to article page